Analysis of the Efficacy of Triamcinolone Acetonide Combined with Ranibizumab in the Treatment of Fundus Diseases  

作　　者：Wanqiu Jiao Jingwei Zhang Ning Ma Zhigang Ma 

机构地区：[1]Harbin Eye Hospital,Harbin 150010,Heilongjiang Province,China

出　　处：《Journal of Clinical and Nursing Research》2023年第6期30-35,共6页临床护理研究（英文）

摘　　要：Objective:To analyze the effect of triamcinolone acetonide combined with ranibizumab in patients with fundus diseases.Methods:100 patients with fundus diseases admitted from January 2018 to January 2023 were selected.The patients were separated into two groups according to the random number table method,with 50 cases in the control group(treated with ranibizumab),and 50 cases in the observation group(treated with triamcinolone acetonide combined with ranibizumab).The clinical effects of both treatment regimens were compared.Results:The time taken for symptom disappearance of the observation group was shorter than that of the control group(P<0.05).The observation group had higher naked-eye visual acuity(4.18±0.89)compared to the control group.Besides,the observation group also had lower intraocular pressure(14.19±1.33 mmHg)and retinal thickness(283.14±3.29μm),with(P<0.05)compared to the control group.Moreover,the observation group had a lower adverse reaction rate and a higher quality of life(P<0.05).Conclusion:The application of triamcinolone acetonide combined with ranibizumab treatment can quickly relieve the clinical symptoms of patients with fundus disease,improve visual acuity,intraocular pressure,and retinal thickness,with low adverse reaction rate and better prognosis and quality of life.

关 键 词：Intravitreal injection of ranibizumab Monoclonal antibody treatment Fundus diseases Adverse reactions Quality of life 

分 类 号：R73[医药卫生—肿瘤]